APA (7th ed.) Citation

A, d. G., R, M., R, d. M., L, S., C, M., ML, M., . . . L, M. (2025). Three-Year Effectiveness of Bictegravir/Emtricitabine/Tenofovir Alafenamide as a Switch Strategy in the Real World. Open forum infectious diseases, 12(3), ofaf087. https://doi.org/10.1093/ofid/ofaf087

Chicago Style (17th ed.) Citation

A, de Gea-Grela, et al. "Three-Year Effectiveness of Bictegravir/Emtricitabine/Tenofovir Alafenamide as a Switch Strategy in the Real World." Open Forum Infectious Diseases 12, no. 3 (2025): ofaf087. https://doi.org/10.1093/ofid/ofaf087.

MLA (9th ed.) Citation

A, de Gea-Grela, et al. "Three-Year Effectiveness of Bictegravir/Emtricitabine/Tenofovir Alafenamide as a Switch Strategy in the Real World." Open Forum Infectious Diseases, vol. 12, no. 3, 2025, p. ofaf087, https://doi.org/10.1093/ofid/ofaf087.